Search results for " recurrent ovarian cancer"

showing 3 items of 3 documents

The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community.

2021

Abstract In the last decade, a growing attention has been focused on identifying effective therapeutic strategies also in the orphan clinical setting of women with platinum-resistant disease. In this context, secondary cytoreductive surgery (SCS) remains a potential approach only in women with platinum sensitive relapse, but experimental data have been published supporting the role of SCS also in patients with platinum-resistant recurrence. In particular, surgery is emerging as a potential option in specific subgroups of women, such as those patients with low-grade serous histology, or low-volume relapse with disease located in the so-called pharmacological sanctuaries. Furthermore, contras…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentContext (language use)Antineoplastic AgentsPlatinum CompoundsDiseaseHyperthermic Intraperitoneal ChemotherapyCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineMedicineAnimalsHumansIn patientPlatinum resistantChemotherapybusiness.industryCytoreduction Surgical Proceduresmedicine.diseaseCombined Modality TherapySurgerySerous fluid030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisPlatinum sensitiveFemaleNeoplasm Recurrence LocalbusinessOvarian cancerBiological features Minimally invasive surgery Personalized treatment Platinum resistant Recurrent ovarian cancer Secondary cytoreductive surgerySeminars in cancer biology
researchProduct

Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?

2015

BACKGROUND: The aim of the present study was to evaluate the efficacy of tertiary and quaternary cytoreduction in recurrent ovarian cancer patients. PATIENTS AND METHODS:Between January 1997 and December 2014, 53 patients were submitted to cytoreductive surgery for second and third ovarian cancer recurrence at our Unit. RESULTS:Median age at first diagnosis was 48 years (range=20-69). Forty-six patients (86.8%) underwent tertiary cytoreduction. At the time of surgery, isolated and diffuse disease was observed in 48 (90.6%) and 5 (9.4%) patients, respectively. Complete and optimal cytoreduction was obtained in 41 (77.5%) and in 1 (1.9%) patients, respectively. We did not observe any statisti…

Ovarian NeoplasmsAdultReoperationCytoreduction Surgical ProcedureMedicine (all)Ovarian NeoplasmTCR QCR cytoreductionRecurrent ovarian cancer; quaternary cytoreduction; tertiary cytoreduction; Adult; Aged; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Recurrence; Local; Ovarian Neoplasms; Reoperation; Survival Analysis; Young Adultquaternary cytoreductionCytoreduction Surgical ProceduresMiddle AgedSurvival AnalysisYoung Adultovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAtertiary cytoreductionHumansFemaleSurvival AnalysiRecurrent ovarian cancerNeoplasm Recurrence Localquaternary cytoreduction; Recurrent ovarian cancer; tertiary cytoreduction; Medicine (all)AgedHuman
researchProduct

Role of Cytoreductive surgery in recurrent ovarian cancer

2010

Ovarian cancer is the leading cause of death from gynecologic malignancy in western countries, primarily because over 60% of patients with ovarian cancer will experience disease recurrence. Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the initial treatment for epithelial ovarian cancer. The management of recurrent ovarian cancer is less clear than that of primary disease. The management of recurrent ovarian cancer is largely based on systemic chemotherapy, with surgery being offered only in selected individuals. Despite this, the benefits of surgery has been shown in a meta-analysis by Bristow et al. where the survival is influenced by the completeness …

Secondary cytoreductionOncologymedicine.medical_specialtyendocrine system diseaseshypertermic intraoperative peritoneal chemotherapyGynecologic oncology; HIPEC; Hyperthermic intraoperative peritoneal chemotherapy; Recurrent ovarian cancer; Secondary cytoreductionGinecologic oncology Hipec recurrent ovarian cancer secondary cytoreductionDiseaseGynecologic oncologyHyperthermic intraoperative peritoneal chemotherapyInternal medicinemedicinePharmacology (medical)Cause of deathHIPECbusiness.industrySystemic chemotherapyCombination chemotherapyGeneral Medicinemedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaGynecologic oncologyGinecologic oncology Hipec recurrent ovarian cancer secondary cytoreduction; hypertermic intraoperative peritoneal chemotherapyRecurrent Ovarian CancerRecurrent ovarian cancerbusinessOvarian cancerCytoreductive surgery
researchProduct